Tag: end stage renal disease (esrd) drug market outlook

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The End Stage Renal Disease (ESRD) Drug Industry Compare Between 2025 And 2029?

The end stage renal disease (esrd) drug market size has observed swift growth in recent years. It is expected to climb from $131.41 billion in 2024 to $148.55 billion in 2025, at a compound annual growth rate (CAGR) of 13.0%. The expansion experienced in earlier periods is linked to the rising incidence of end stage renal disease, an expanding aging demographic, better access to healthcare provisions, various government initiatives and policies, and the increasing embrace of renal replacement therapies.

The end stage renal disease (esrd) drug market size is poised for substantial growth in the upcoming years. It is predicted to expand to $262.76 billion by 2029, achieving a compound annual growth rate (CAGR) of 15.3%. This anticipated growth is primarily fueled by the advent of new therapies and pharmaceutical innovations, increasing spending within the healthcare sector, the escalating worldwide prevalence of chronic kidney diseases, the adoption of personalized medicine techniques, and robust regulatory backing combined with streamlined approval processes. Significant trends during this forecast period encompass a rising incidence of end stage renal disease, continuous advancements in treatment options, a heightened focus on precision medicine, the development of multi-drug combination therapies, and the increasing integration of technology into healthcare practices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Are The Main Drivers Boosting The End Stage Renal Disease (ESRD) Drug Industry’s Expansion?

The escalating instances of obesity and diabetes are anticipated to stimulate the expansion of the end-stage renal disease (ESRD) drug market moving forward. Obesity is characterized as an abnormal or excessive accumulation of fat that poses health risks. In contrast, diabetes is a chronic condition that arises either when the pancreas does not produce sufficient insulin or when the body is unable to effectively utilize the insulin it generates. For patients with renal disease, managing fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis can enhance overall health and well-being, potentially leading to weight reduction and improved blood sugar control. For instance, in March 2022, World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, stated that the number of obese people is expected to increase to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in February 2023, according to the National Health Service, the UK-based publicly funded healthcare system, it is estimated that by 2030, the number of people in the UK with diabetes could reach 5.5 million, impacting nearly 9% of the population. Therefore, the increasing prevalence of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

What Are The Different Segment Classifications Within The End Stage Renal Disease (ESRD) Drug Market?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Which Competitive Trends Are Defining The End Stage Renal Disease (ESRD) Drug Market Structure?

Product innovation represents a key trend enhancing popularity within the end-stage renal disease (ESRD) drug market. Leading companies in the end-stage renal disease (ESRD) drug market are primarily focused on creating innovative solutions to maintain their position. As an example, in April 2022, GlaxoSmithKline PLC, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat. This oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is intended for the potential treatment of patients suffering from chronic kidney disease anemia (CKD). The foundation of this new product lies in unique Nobel prize-winning science that demonstrated how cells sense and adapt to oxygen availability.

Which Leading Companies Dominate The End Stage Renal Disease (ESRD) Drug Market Share?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

How Do Regional Market Performances Compare Within The End Stage Renal Disease (ESRD) Drug Industry?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The End Stage Renal Disease (ESRD) Drug Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The End Stage Renal Disease (ESRD) Drug Market Be Worth By 2029?

Recent years have seen a rapid expansion in the market size of drugs for end stage renal disease (esrd). Current expectations indicate this market will expand from $131.41 billion in 2024 to $148.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.0%. This impressive historic growth rate is largely due to factors such as an increase in cases of end stage renal disease, an aging population, better access to healthcare services, governmental initiatives and regulations, and a higher acceptance of renal replacement therapies.

The market size of drugs for end stage renal disease (esrd) is projected to experience swift expansion in the upcoming years. The market is anticipated to reach a valuation of “$262.76 billion by 2029 with a compound annual growth rate (CAGR) of 15.3%. The expansion projected within this period can be tied to factors such as new therapies and drug innovations, an increase in healthcare spending, a growing worldwide prevalence of chronic kidney disorders, the growing trend of personalized medicine, regulatory support, and timely approvals. Key trends for this period include a rising occurrence of end stage renal disease, advancements in treatment techniques, greater focus on precision medicine, the introduction of combined therapies, and technological incorporation in healthcare.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

Which Industry Forces Are Driving The End Stage Renal Disease (ESRD) Drug Market Forward?

The end-stage renal disease (ESRD) drug market is anticipated to experience significant growth due to the increasing prevalence of obesity and diabetes. Obesity is characterized by excessive or abnormal accumulation of fat that presents health risks, while diabetes is a long-term condition that occurs when the body does not produce enough insulin or cannot effectively use the insulin it does produce. Managing fluid, electrolyte levels, blood pressure, and waste product elimination through dialysis in renal disease patients can enhance their general health, potentially leading to weight loss and better blood sugar management. For example, World Obesity, a membership organization based in the US that focuses on obesity research and management, forecasts that the number of obese individuals could increase to 892 million in 2025, and further surge to 1.025 billion in 2030. Moreover, the National Health Service, a UK-based public health service, projects that by 2030, the UK could have up to 5.5 million people with diabetes, affecting nearly 9% of the population. Consequently, the escalating instances of obesity and diabetes are expected to fuel the demand for ESRD drugs.

What Are The Key Segment Trends Observed In The End Stage Renal Disease (ESRD) Drug Market?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Which Disruptive Trends Are Driving Change Across The End Stage Renal Disease (ESRD) Drug Market?

Driving the end-stage renal disease (ESRD) drug market’s popularity is the major trend of product innovation. Big players in the ESRD drug market are concentrating on the creation of novel solutions to maintain market relevance. For instance, in April 2022, UK pharmaceutical and biotechnology giant, GlaxoSmithKline PLC, announced that their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), was accepted by the US Food and Drug Administration (FDA). The acceptance was for its potential use in treating chronic kidney disease anemia (CKD). This innovative product is rooted in the exceptional Nobel prize-winning research demonstrating how cells perceive and modify to oxygen supply.

Which Firms Are Driving Innovation Within The End Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What Regional Factors Are Accelerating Growth In The End Stage Renal Disease (ESRD) Drug Market?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the End Stage Renal Disease (ESRD) Drug Industry?

The market size of drugs for end stage renal disease (esrd) has experienced a fast-paced expansion in the past few years. The market, which was worth $131.41 billion in 2024, is projected to reach $148.55 billion in 2025, displaying a compound annual growth rate (CAGR) of 13.0%. The growth observed in the historical period can be attributed to factors such as the rising prevalence of end stage renal disease, an increasing elderly population, enhanced healthcare services accessibility, government initiatives and policies, and growing acceptance of renal replacement therapies.

The market for end stage renal disease (esrd) medication is anticipated to experience significant expansion in the coming years. It’s projected to increase to “$262.76 billion by 2029 with a compound annual growth rate (CAGR) of 15.3%. The expected growth during this period can be ascribed to the introduction of new therapies and drug breakthroughs, enhanced healthcare spending, the escalating worldwide impact of chronic kidney disorders, personalized treatment methodologies, regulatory backing, and accelerated approvals. Key trends predicted for this forecast period include a rising prevalence of end stage renal disease, improvements in treatment processes, heightened focus on precision medicine, the emergence of combined therapies, and technological advancements in healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Forces Are Driving The Growth Of The End Stage Renal Disease (ESRD) Drug Industry?

The end-stage renal disease (ESRD) drug market is predicted to experience increased growth due to the escalating rates of obesity and diabetes. Obesity, which refers to the unhealthy and excessive accumulation of fat in the body, and diabetes, a chronic ailment caused by the pancreas’ inability to produce sufficient insulin or the body’s inefficiency in using the insulin, pose significant health threats. These conditions can be mitigated in renal disease patients via fluid and electrolyte level management, blood pressure regulation, and dialysis, which eliminates waste products from the body, contributing to general health improvements, weight loss, and better blood sugar control. For example, as recorded by World Obesity in March 2022, a U.S. membership organization focused on studying and managing obesity, the population of obese individuals is anticipated to climb to 892 million by 2025 and further to 1,025 million by 2030. Additionally, the National Health Service, a publicly funded healthcare system based in the UK, projected in February 2023 that the number of UK residents suffering from diabetes could reach up to 5.5 million by 2030, affecting nearly 9% of the nation’s population. Consequently, the increasing trends in obesity and diabetes cases are anticipated to boost the ESRD drug market.

What Is The Overview Of Market Segmentation In The End Stage Renal Disease (ESRD) Drug Industry?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

How Are Key Trends Driving Expansion In The End Stage Renal Disease (ESRD) Drug Industry?

Introducing fresh products is a significant trend for achieving prominence in the end-stage renal disease (ESRD) drug market. Leading corporations in the ESRD drug sector are zeroing in on the production of inventive solutions to maintain their presence in the market. For instance, in April 2022, the US Food and Drug Administration (FDA) approved a New Drug Application (NDA) from GlaxoSmithKline PLC – a pharmaceutical and biotech company based in the UK. The application was for daprodustat, an orally consumed hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) – potentially catering to the treatment of patients with chronic kidney disease anemia (CKD). This innovative product is rooted in a unique Nobel prize-awarded scientific breakthrough that revealed how cells can detect and adjust to the levels of oxygen present.

Who Are The Primary Players Operating Across The Global End Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Which Region Offers The Most Growth Potential For The End Stage Renal Disease (ESRD) Drug Market Through 2029?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the End Stage Renal Disease (ESRD) Drug Industry?

Recent years have seen a significant expansion in the market size of the end stage renal disease (esrd) drug. The market is expected to balloon from $131.41 billion in 2024 to $148.55 billion in 2025, representing a compound annual growth rate (CAGR) of 13.0%. This surge in the past period can be credited to various factors including the rising incidences of end stage renal disease, an aging population demographic, enhanced accessibility to healthcare services, strategic government initiatives and policies, along with an increased uptake of renal replacement therapies.

In the upcoming years, a swift expansion is predicted for the market size of end stage renal disease (esrd) drugs, with an projected growth to $262.76 billion by 2029, displaying a compound annual growth rate (CAGR) of 15.3%. This growth rate during the forecast period can be credited to the advent of new therapies and drug innovations, amplified health care spending, escalating global incidence of chronic kidney diseases, personalized treatment strategies, regulatory backing, and fast-tracked endorsements. Key trends for this forecasting period consist of an escalating occurrence of end stage renal disease, improvements in treatment methods, a rising focus on precision medicine, the progress of combination therapies, and the incorporation of technology in healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Forces Are Driving The Growth Of The End Stage Renal Disease (ESRD) Drug Industry?

The surge in obesity and diabetes cases is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity refers to an abnormal or excessive accumulation of fat that poses a health risk, while diabetes is a chronic illness characterized by the pancreas’ inability to produce adequate insulin or the body’s inefficient use of the produced insulin. For patients suffering from renal disease, fluid and electrolyte level management, blood pressure regulation, and elimination of waste products via dialysis can enhance overall health and wellness. This could potentially lead to weight loss and better blood sugar control. For example, World Obesity, a U.S.-based membership organization dedicated to the study and management of obesity, projected in March 2022 that the number of obese individuals could escalate to 892 million in 2025 and further to 1,025 million in 2030. Moreover, the National Health Service in the UK, a publicly funded healthcare system, estimated in February 2023 that by 2030, around 5.5 million people in the UK, nearly 9% of the population, could be diagnosed with diabetes. Consequently, the upswing in obesity and diabetes cases will boost the end-stage renal disease (ESRD) drug market.

What Is The Overview Of Market Segmentation In The End Stage Renal Disease (ESRD) Drug Industry?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Future Market Trends Are Projected For The End Stage Renal Disease (ESRD) Drug Industry?

Strategic product advancements are emerging as a significant trend for achieving market traction in the end-stage renal disease (ESRD) drug market. The leading companies in the ESRD drug market are resorting to the development of groundbreaking solutions to maintain their market foothold. For instance, in April 2022, GlaxoSmithKline PLC, a biotech and pharmaceutical company located in the UK, confirmed that the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) potentially used for treating chronic kidney disease anemia (CKD), was accepted by the US Food and Drug Administration (FDA). This novel product is built upon the unique, Nobel prize-winning research that validated how cells detect and accommodate to the presence of oxygen.

Who Are The Primary Players Operating Across The Global End Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Which Region Offers The Most Growth Potential For The End Stage Renal Disease (ESRD) Drug Market Through 2029?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the End Stage Renal Disease (ESRD) Drug Market Growth in 2025?

The market for drugs treating end stage renal disease (ESRD) has experienced significant expansion lately. Forecasts predict its size to increase from $131.41 billion in 2024 to $149.88 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.1%. The historical growth can be attributed to a higher incidence of ESRD, a rising elderly population, better access to healthcare services, government actions and policies, as well as an uptick in the utilization of renal replacement therapies.

What Is the Forecast for the End Stage Renal Disease (ESRD) Drug Market Size Through 2029?

In the coming years, the market size for drugs treating end stage renal disease (ESRD) is projected to witness a swift expansion. The expected growth rate will peak at $268.44 billion in 2029 with a compound annual growth rate (CAGR) of 15.7%. The anticipated growth in this period can be related to the advent of innovative drugs and therapies, augmented healthcare spending, heightened global chronic kidney disease incidences, personalized treatment methods, supportive regulations, and accelerated approval processes. The key trends for this period consist of the rising prevalence of end stage renal disease, progress in treatment methods, a heightened focus on precision medicine, the inception of combination therapies, and the incorporation of technology in healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What are the Key Market Players in End Stage Renal Disease (ESRD) Drug Market and How They’re Evolving?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

What Are the Primary Growth Drivers in the End Stage Renal Disease (ESRD) Drug Market?

The escalating incidence of obesity and diabetes is projected to fuel the expansion of the end-stage renal disease (ESRD) drug market in the future. Obesity is characterized as unusually high or disproportionate accumulation of fat, presenting a risk to health. Conversely, diabetes is an enduring disease that occurs when either the pancreas fails to generate sufficient insulin or the body is unable to optimally use the insulin that is produced. The management of fluid and electrolyte levels, blood pressure, and the elimination of waste products through dialysis can enhance the overall health and comfort of patients with kidney diseases, possibly resulting in weight loss and better control of blood sugar. For instance, World Obesity, a US-based organization representing national and regional societies committed to obesity research and treatment, reported in March 2022 that the number of obese individuals is expected to escalate to 892 million by 2025 and further to 1,025 million by 2030. Moreover, as per the National Health Service, a publicly financed healthcare system based in the UK, by 2030, it is predicted that the count of people with diabetes in the UK could escalate to 5.5 million, implicating almost 9% of the population. Consequently, the increasing instances of obesity and diabetes are set to propel the market growth of end-stage renal disease (ESRD) drugs.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

What Are the Leading Segments in the Global End Stage Renal Disease (ESRD) Drug Industry?

The end stage renal disease (ESRD) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Are the Key Market Trends in the End Stage Renal Disease (ESRD) Drug Industry?

In the end-stage renal disease (ESRD) drug market, a proactive focus on product developments is becoming a crucial strategy to gain traction. Leading entities in the ESRD drug sector are emphasizing inventive solutions to maintain their market standing. One such example is the announcement made in April 2022 by GlaxoSmithKline PLC, a pioneer in the pharmaceutical and biotech industry hailing from the UK. They revealed that the US Food and Drug Administration (FDA) has endorsed their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), targeted to potentially assist patients battling chronic kidney disease anemia (CKD). This innovative product draws from the exclusive Nobel prize-winning scientific discovery elucidating how cells perceive and adjust to the level of available oxygen.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What Is the Regional Outlook for the End Stage Renal Disease (ESRD) Drug Market?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437

This Report Delivers Insight On:

1. How big is the end stage renal disease (esrd) drug market, and how is it changing globally?

2. Who are the major companies in the end stage renal disease (esrd) drug market, and how are they performing?

3. What are the key opportunities and risks in the end stage renal disease (esrd) drug market right now?

4. Which products or customer segments are growing the most in the end stage renal disease (esrd) drug market?

5. What factors are helping or slowing down the growth of the end stage renal disease (esrd) drug market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the end stage renal disease (esrd) drug industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the End Stage Renal Disease (ESRD) Drug Market Through 2034?

The market size for drugs catering to end stage renal disease (ESRD) has swiftly expanded in the past few years. It is set to increase from a substantial $131.41 billion in 2024 to an impressive $149.88 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%. The remarkable growth in the historic duration can be ascribed to a rise in the occurrence of end stage renal disease, the aging population, enhanced access to healthcare services, governmental initiatives and policies, along with an increased uptake of renal replacement therapies.

The market size of drugs for end stage renal disease (ESRD) is projected to experience a swift rise in the imminent years. Its expected growth to $268.44 billion in 2029 at a compound annual growth rate (CAGR) of 15.7% can be ascribed to factors such as developing therapies, innovation in drugs, escalated healthcare spending, the growing global prevalence of chronic kidney disorders, individualized medication approaches, regulatory aid, and swift approvals. The forecast period is likely to be characterized by major trends including a rising incidence of end stage renal disease, progress in treatment methods, an increased focus on precision medicine, the creation of combined therapies, and the incorporation of technology in healthcare.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What External and Internal Drivers Are Contributing to the Growth of the End Stage Renal Disease (ESRD) Drug Market?

The increase in obesity and diabetes prevalence is projected to accelerate the expansion of the end-stage renal disease (ESRD) drug market. Obesity refers to unusual or excessive fat accumulation that raises health risks, while diabetes is a long-term disorder that occurs when the body either fails to produce enough insulin or can’t effectively use the generated insulin. In the context of renal disease, maintaining fluid and electrolyte balance, controlling blood pressure, and removing waste products through dialysis can enhance overall health leading to possible weight loss and improved control of blood sugar levels. For example, in March 2022, as per World Obesity, an American membership organization that represents national and regional groups committed to the research and treatment of obesity, the worldwide obesity count is projected to jump to 892 million by 2025, increasing further to 1,025 million in 2030. Moreover, in February 2023, the national health service of UK, a publicly funded healthcare system, estimated that by 2030, about 5.5 million people in the UK might have diabetes, which would affect almost 9% of its total population. Therefore, the escalation in obesity and diabetes instances will positively influence the demand for end-stage renal disease (ESRD) drugs.

What Segment Types Define the End Stage Renal Disease (ESRD) Drug Market Structure?

The end stage renal disease (ESRD) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the End Stage Renal Disease (ESRD) Drug Market?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the End Stage Renal Disease (ESRD) Drug Market?

In the end-stage renal disease (ESRD) drug market, one of the key strategies for gaining traction is product innovation. Large-scale companies in this market are putting their focus on creating unique solutions to keep up with the competition. For instance, a notable event in April 2022 saw the US Food and Drug Administration (FDA) acknowledge the New Drug Application (NDA) from GlaxoSmithKline PLC, a pharmaceutical and biotechnology company from the UK. The drug in question, daprodustat, an orally taken hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), holds potential in treating those suffering from chronic kidney disease anemia (CKD). What sets this new product apart is the utilization of exclusive, Nobel prize-winning science which demonstrates how cells adapt and respond to the presence of oxygen.

View the full report here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What Is the Definition of the End Stage Renal Disease (ESRD) Drug Market?

End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theEnd Stage Renal Disease (ESRD) Drug Market?

The increasing prevalence of obesity and diabetes is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity, defined as an unusually high and unhealthy accumulation of fat, and diabetes, a long-term condition where the pancreas doesn’t produce sufficient insulin or the body is unable to use it effectively, are both health risks. Individuals with renal diseases can enhance their overall health by managing fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis. This could potentially lead to weight loss and better control of blood sugar levels. For example, World Obesity, a US-based organization focused on the study and management of obesity, predicted in March 2022 that the global obesity count could surge to 892 million in 2025, then further to 1,025 million in 2030. Similarly, the UK’s National Health Service projected in February 2023 that by 2030, the number of people with diabetes in the UK could escalate to 5.5 million, affecting almost 9% of the population. Hence, the growing instances of obesity and diabetes are expected to push the demand for ESRD drugs.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

#How Does the ProjectedEnd Stage Renal Disease (ESRD) Drug Market Growth Compare Over the Forecast Period?

The market size for drugs used in the treatment of end stage renal disease (ESRD) has experienced a swift expansion in recent years. There is projected growth from $131.41 billion in 2024 to $149.88 billion in 2025, showing a compound annual growth rate (CAGR) of 14.1%. Factors contributing to the growth during the historic period include rising cases of end stage renal disease, growth in the elderly population, better access to healthcare facilities, beneficial government strategies and policies, along with an increased uptake of renal replacement therapies.

In the coming years, the market size for drugs treating end stage renal disease (ESRD) is projected to expand rapidly, reaching $268.44 billion by 2029, propelled by a compound annual growth rate (CAGR) of 15.7%. This predicted growth in the forecast period stems from factors such as emerging drug therapies and innovative medicines, an escalation in healthcare spending, the rising global prevalence of chronic kidney diseases, personalized treatment strategies, supportive regulatory environments, and swift approvals of new treatments. The forecast period will also witness major trends including greater incidence of end stage renal disease, progress in treatment modalities, increased focus on precision medicine, the rise of combination therapies, and technological integration within the healthcare sector.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437

Which Upcoming Market Trends and Innovations Are Set to Influence theEnd Stage Renal Disease (ESRD) Drug Market’s Path Forward?

The rise in product innovations is a primary factor driving the popularity in the end-stage renal disease (ESRD) drug market. To remain competitive, leading companies in the ESRD drug market are focusing on the creation of innovative solutions. For example, in April 2022, UK-based pharmaceutical and biotechnology company GlaxoSmithKline PLC announced that their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has been approved by the US Food and Drug Administration (FDA) for potential treatment of patients with chronic kidney disease anemia (CKD). This breakthrough product is founded on the unique, Nobel-prize awarded scientific discovery that demonstrates how cells detect and adapt to the availability of oxygen.

Who Are the Dominant Market Players Pushing the Boundaries of theEnd Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What Are the Core Segments of the End Stage Renal Disease (ESRD) Drug Market, and How Do They Contribute to Growth?

The end stage renal disease (ESRD) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smpGlobal End Stage Renal Disease (ESRD) Drug Market, Global End Stage Renal Disease (ESRD) Drug Market Report, Global End Stage Renal Disease (ESRD) Drug Market Trends, Global End Stage Renal Disease (ESRD) Drug Market Size

Browse Through More Reports Similar to the Gobal End Stage Renal Disease (ESRD) Drug Maret 2025, By The Business Research Company:

Musculoskeletal Disorders Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Central Nervous System Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cardiovascular Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the end stage renal disease (esrd) drug market grown over the years?

Recent years have seen a sharp increase in the size of the end stage renal disease (ESRD) drug market. It is anticipated to escalate from $131.41 billion in 2024 to $149.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.1%. The previous growth can be credited to a rising prevalence of end stage renal disease, an expanding elderly population, better access to health care services, governmental actions and regulations, and a greater acceptance of renal replacement therapies.

What Is the forecasted market size and growth rate for the end stage renal disease (esrd) drug market?

The market size for end stage renal disease (ESRD) medications is anticipated to witness swift expansion in the upcoming years. Forecasted to rise to $268.44 billion in 2029 with a 15.7% compound annual growth rate (CAGR), this growth within the projected period is credited to the emergence of new therapies and medication advancements, heightened healthcare spending, escalating global incidences of chronic kidney illnesses, tailored medical strategies, regulatory backing, and expedited clearance processes. Key trends in the projection period encompass the escalating cases of end stage renal disease, progression in treatment methods, increasing concentration on precision medicine, the evolution of combined therapies, and the inclusion of technology within healthcare.

Get your end stage renal disease (esrd) drug market report here!

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

What are the major factors driving growth in the end stage renal disease (esrd) drug market?

The increasing prevalence of obesity and diabetes is predicted to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity refers to an excessive or irregular accumulation of fat that is detrimental to health, whereas diabetes is a long-term condition associated with the pancreas not producing sufficient insulin or the body’s inability to effectively use the produced insulin. For patients experiencing renal diseases, it’s crucial to manage fluid and electrolyte levels, blood pressure, and eliminate waste products through dialysis. This helps enhance overall health, potentially promoting weight loss and improving blood sugar levels. For example, World Obesity, a US-based organization focused on obesity research and management, projected in March 2022 that the global obesity figure could hit 892 million by 2025 and increase to 1,025 million by 2030. Furthermore, in February 2023, according to the National Health Service, a public healthcare system in the UK, it was projected that by 2030, the UK could see up to 5.5 million diabetes patients, implying nearly 9% of the population. Consequently, this surge in obesity and diabetes cases is expected to augment the ESRD drug market.

What key areas define the segmentation of the global end stage renal disease (esrd) drug Market?

The end stage renal disease (ESRD) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What are the top market players propelling the growth of the end stage renal disease (esrd) drug industry?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

What are the key trends shaping the future of the end stage renal disease (esrd) drug market?

In the end-stage renal disease (ESRD) drug market, the trend of product innovation is crucial for gaining traction. Major corporations involved in the ESRD drug market are concentrating on creating innovative solutions to remain competitive. For instance, in April 2022, GlaxoSmithKline PLC, a pharmaceutical and biotechnology company from the UK, declared that the US Food and Drug Administration (FDA) has approved their New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). This could potentially be used to treat patients with chronic kidney disease anaemia (CKD). The novelty of this product is rooted in the unprecedented Nobel prize-winning research which demonstrated how cells sense and adapt to changes in oxygen levels.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437

What regions are dominating the end stage renal disease (esrd) drug market growth?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Musculoskeletal Disorders Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Central Nervous System Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cardiovascular Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Growth Opportunities are Expected to Drive the End Stage Renal Disease ESRD Drug Market’s CAGR Through 2034?

The market size for end-stage renal disease (ESRD) drug has experienced swift growth in recent years, expanding from $131.41 billion in 2024 to an anticipated $149.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.1%. The unprecedented growth recorded in the historical period can be traced back to rising cases of end stage renal disease, a burgeoning elderly population, enhanced accessibility to healthcare services, governmental strategies and guidelines, and the increasing uptake of renal replacement therapies.

The market for drugs treating end stage renal disease (ESRD) is predicted to witness rapid expansion in the upcoming years, with the projected size expected to reach $268.44 billion by 2029, reflecting a compound annual growth rate (CAGR) of 15.7%. The anticipated growth during the forecast period can be ascribed to the development of new therapies and innovative drugs, increased spending on healthcare, the escalating worldwide incidence of chronic kidney diseases, individualized medical treatment strategies, regulatory assistance, and faster approval processes. Key trends during the forecast period encompass the rising prevalence of end stage renal disease, improvements in treatment methods, increasing focus on precision medicine, the creation of hybrid therapies, and the incorporation of technology in healthcare.

What Major Innovations Are Driving the Accelerated Growth of the end stage renal disease esrd drug Market?

The surge in obesity and diabetes is anticipated to fuel the progression of the end-stage renal disease (ESRD) drug market. Obesity is characterized as abnormal or excess fat accumulation that constitutes a health risk, while diabetes is a long-term condition that occurs when the pancreas fails to produce sufficient insulin or the body is unable to use the insulin produced effectively. In renal disease patients, maintaining fluid and electrolyte levels, blood pressure, and the elimination of waste products through dialysis can enhance overall health and potential weight loss, thus improving blood sugar management. For example, World Obesity, a US-based member organization dedicated to obesity study and management, projected in March 2022 that the number of obese individuals could escalate to 892 million by 2025 and then to 1,025 million by 2030. Moreover, the National Health Service, a UK-based publicly funded healthcare system, predicted in February 2023 that the number of diabetics in the UK might hit 5.5 million by 2030, affecting nearly 9% of the populace. Hence, the increasing prevalence of obesity and diabetes is set to catalyze the end-stage renal disease (ESRD) drug market.

Get Your Free Sample of the Global End Stage Renal Disease ESRD Drug Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Are the Top Market Players Propelling the Growth of the End Stage Renal Disease ESRD Drug Industry?

Major companies operating in the end stage renal disease (ESRD) drug market include:

• Pfizer Inc._x000D_

• AstraZeneca plc_x000D_

• Sanofi SA_x000D_

• Astellas Pharma Inc._x000D_

• Novartis AG_x000D_

What Are the Key Trends to Watch in the End Stage Renal Disease ESRD Drug Market Over the Coming Years?

A significant trend observed in the end-stage renal disease (ESRD) drug market is the prioritization of product innovations. Leading entities in the ESRD drug market are prioritizing innovative solutions to maintain their foothold in the market. For instance, April 2022 saw GlaxoSmithKline PLC, a renowned pharmaceutical and biotechnology company from the UK, inform the public that the US Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for daprodustat. This drug is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and could potentially treat patients with chronic kidney disease anemia (CKD). The foundation of this unique product lies in the Nobel-prize winning research that explores how cells adapt to changes in oxygen availability.

Get Instant Access to the Global End Stage Renal Disease ESRD Drug Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

How Are Market Segments in the End Stage Renal Disease ESRD Drug Industry Positioned for Long-Term Growth?

The end stage renal disease (ESRD) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Regions Are Dominating the End Stage Renal Disease ESRD Drug Market Growth?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Key Characteristics That Define the End Stage Renal Disease ESRD Drug Market?

End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).

Browse Through More Similar Reports By The Business Research Company:

Musculoskeletal Disorders Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Central Nervous System Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cardiovascular Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: